Analysts Set Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Price Target at $9.33

Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) have received a consensus rating of "Hold" from the ten brokerages that are currently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, six have assigned a hold recommendation and three have given a buy recommendation to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $9.33.

A number of equities research analysts have recently issued reports on the stock. Leerink Partnrs downgraded shares of Fulcrum Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Thursday, September 12th. Stifel Nicolaus cut Fulcrum Therapeutics from a "buy" rating to a "hold" rating and reduced their target price for the stock from $22.00 to $3.00 in a report on Thursday, September 12th. Leerink Partners restated a "market perform" rating and issued a $4.00 price target on shares of Fulcrum Therapeutics in a research report on Thursday, September 12th. Cantor Fitzgerald downgraded Fulcrum Therapeutics from an "overweight" rating to a "neutral" rating in a research report on Thursday, September 12th. Finally, Bank of America cut shares of Fulcrum Therapeutics from a "neutral" rating to an "underperform" rating and dropped their target price for the stock from $10.00 to $2.00 in a report on Thursday, September 12th.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. National Bank of Canada FI boosted its position in shares of Fulcrum Therapeutics by 869.6% in the second quarter. National Bank of Canada FI now owns 4,460 shares of the company's stock worth $28,000 after buying an additional 4,000 shares during the period. China Universal Asset Management Co. Ltd. lifted its position in Fulcrum Therapeutics by 64.4% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 12,002 shares of the company's stock valued at $43,000 after purchasing an additional 4,701 shares during the last quarter. Walleye Capital LLC bought a new stake in Fulcrum Therapeutics during the 3rd quarter valued at $59,000. Intech Investment Management LLC bought a new stake in shares of Fulcrum Therapeutics during the 3rd quarter worth about $62,000. Finally, Profund Advisors LLC acquired a new stake in shares of Fulcrum Therapeutics in the second quarter valued at $68,000. 89.83% of the stock is currently owned by institutional investors and hedge funds.

Fulcrum Therapeutics Trading Down 8.4 %

Fulcrum Therapeutics stock traded down $0.41 during mid-day trading on Thursday, hitting $4.48. The company had a trading volume of 646,720 shares, compared to its average volume of 575,604. The company has a market capitalization of $241.65 million, a PE ratio of -14.45 and a beta of 2.06. Fulcrum Therapeutics has a 12 month low of $2.86 and a 12 month high of $13.70. The stock's 50 day moving average price is $3.97 and its two-hundred day moving average price is $5.54.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.